Better end points needed in primary sclerosing cholangitis trials
A new study of a fibroblast growth factor 19 analogue in patients with primary sclerosing cholangitis (PSC) provides provocative results. The data challenge alkaline phosphatase levels as the appropriate surrogate end point in PSC trials and highlight alternatives, urging efforts to identify better...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Gastroenterology & hepatology 2019-03, Vol.16 (3), p.143-144 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 144 |
|---|---|
| container_issue | 3 |
| container_start_page | 143 |
| container_title | Nature reviews. Gastroenterology & hepatology |
| container_volume | 16 |
| creator | Gerussi, Alessio Invernizzi, Pietro |
| description | A new study of a fibroblast growth factor 19 analogue in patients with primary sclerosing cholangitis (PSC) provides provocative results. The data challenge alkaline phosphatase levels as the appropriate surrogate end point in PSC trials and highlight alternatives, urging efforts to identify better clinical end points for this disease. |
| doi_str_mv | 10.1038/s41575-019-0110-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179406158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A576092705</galeid><sourcerecordid>A576092705</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-d69eb11500e46c22de6891832cf3e48c8201c77d210fd99d1887e03073cb3c673</originalsourceid><addsrcrecordid>eNp1kd9rFDEQx4NYbD39A3yRBUF82ZpJNpvk8Sz-KBR80eewl8zepewlZ5J98L83y11bK5YQZkg-32FmvoS8AXoJlKuPuQMhRUtB1wu0Fc_IBUihW0EFf36fd-KcvMz5ltJeCK5fkHO-ZD1nF2T9CUvB1GBwzSH6UHITEB26xofmkPx-SL-bbCdMMfuwbewuTkPY-uJzU5IfpvyKnI014OtTXJGfXz7_uPrW3nz_en21vmltJ2lpXa9xAyAoxa63jDnslQbFmR05dsoqRsFK6RjQ0WntQCmJlFPJ7YbbXvIV-XCse0jx14y5mL3PFqfaDsY5GwZSd7QHoSr67h_0Ns4p1O4qpSoCTMADtR0mND6MsaTBLkXNWsieaibrGlfk8j9UPQ733saAo6_vjwTv_xLscJjKLsdpLj6G_BiEI2jrbnPC0Zz2bYCaxV9z9NdUf83ir1k0b0-TzZs9unvFnaEVYEcg16-wxfQw-tNV_wALequy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2186151251</pqid></control><display><type>article</type><title>Better end points needed in primary sclerosing cholangitis trials</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Gerussi, Alessio ; Invernizzi, Pietro</creator><creatorcontrib>Gerussi, Alessio ; Invernizzi, Pietro</creatorcontrib><description>A new study of a fibroblast growth factor 19 analogue in patients with primary sclerosing cholangitis (PSC) provides provocative results. The data challenge alkaline phosphatase levels as the appropriate surrogate end point in PSC trials and highlight alternatives, urging efforts to identify better clinical end points for this disease.</description><identifier>ISSN: 1759-5045</identifier><identifier>EISSN: 1759-5053</identifier><identifier>DOI: 10.1038/s41575-019-0110-5</identifier><identifier>PMID: 30655632</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308/2779/109 ; 692/308/409 ; 692/699/1503/1607/2744 ; 692/700/565/1436 ; Alkaline phosphatase ; Analysis ; Bile acids ; Biomedicine ; Cholangitis ; Cholangitis, Sclerosing ; Clinical trials ; Deoxycholic acid ; Double-Blind Method ; Drug therapy ; Fibroblast Growth Factors ; Gastroenterology ; Hepatology ; Homeostasis ; Humans ; Liver ; Liver diseases ; Medicine ; Medicine & Public Health ; Metronidazole ; News & Views ; news-and-views ; Phosphatases ; Surgery</subject><ispartof>Nature reviews. Gastroenterology & hepatology, 2019-03, Vol.16 (3), p.143-144</ispartof><rights>Springer Nature Limited 2019</rights><rights>COPYRIGHT 2019 Nature Publishing Group</rights><rights>2019© Springer Nature Limited 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-d69eb11500e46c22de6891832cf3e48c8201c77d210fd99d1887e03073cb3c673</citedby><cites>FETCH-LOGICAL-c470t-d69eb11500e46c22de6891832cf3e48c8201c77d210fd99d1887e03073cb3c673</cites><orcidid>0000-0002-5086-0514</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41575-019-0110-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41575-019-0110-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30655632$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gerussi, Alessio</creatorcontrib><creatorcontrib>Invernizzi, Pietro</creatorcontrib><title>Better end points needed in primary sclerosing cholangitis trials</title><title>Nature reviews. Gastroenterology & hepatology</title><addtitle>Nat Rev Gastroenterol Hepatol</addtitle><addtitle>Nat Rev Gastroenterol Hepatol</addtitle><description>A new study of a fibroblast growth factor 19 analogue in patients with primary sclerosing cholangitis (PSC) provides provocative results. The data challenge alkaline phosphatase levels as the appropriate surrogate end point in PSC trials and highlight alternatives, urging efforts to identify better clinical end points for this disease.</description><subject>692/308/2779/109</subject><subject>692/308/409</subject><subject>692/699/1503/1607/2744</subject><subject>692/700/565/1436</subject><subject>Alkaline phosphatase</subject><subject>Analysis</subject><subject>Bile acids</subject><subject>Biomedicine</subject><subject>Cholangitis</subject><subject>Cholangitis, Sclerosing</subject><subject>Clinical trials</subject><subject>Deoxycholic acid</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Fibroblast Growth Factors</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metronidazole</subject><subject>News & Views</subject><subject>news-and-views</subject><subject>Phosphatases</subject><subject>Surgery</subject><issn>1759-5045</issn><issn>1759-5053</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kd9rFDEQx4NYbD39A3yRBUF82ZpJNpvk8Sz-KBR80eewl8zepewlZ5J98L83y11bK5YQZkg-32FmvoS8AXoJlKuPuQMhRUtB1wu0Fc_IBUihW0EFf36fd-KcvMz5ltJeCK5fkHO-ZD1nF2T9CUvB1GBwzSH6UHITEB26xofmkPx-SL-bbCdMMfuwbewuTkPY-uJzU5IfpvyKnI014OtTXJGfXz7_uPrW3nz_en21vmltJ2lpXa9xAyAoxa63jDnslQbFmR05dsoqRsFK6RjQ0WntQCmJlFPJ7YbbXvIV-XCse0jx14y5mL3PFqfaDsY5GwZSd7QHoSr67h_0Ns4p1O4qpSoCTMADtR0mND6MsaTBLkXNWsieaibrGlfk8j9UPQ733saAo6_vjwTv_xLscJjKLsdpLj6G_BiEI2jrbnPC0Zz2bYCaxV9z9NdUf83ir1k0b0-TzZs9unvFnaEVYEcg16-wxfQw-tNV_wALequy</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Gerussi, Alessio</creator><creator>Invernizzi, Pietro</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5086-0514</orcidid></search><sort><creationdate>20190301</creationdate><title>Better end points needed in primary sclerosing cholangitis trials</title><author>Gerussi, Alessio ; Invernizzi, Pietro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-d69eb11500e46c22de6891832cf3e48c8201c77d210fd99d1887e03073cb3c673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>692/308/2779/109</topic><topic>692/308/409</topic><topic>692/699/1503/1607/2744</topic><topic>692/700/565/1436</topic><topic>Alkaline phosphatase</topic><topic>Analysis</topic><topic>Bile acids</topic><topic>Biomedicine</topic><topic>Cholangitis</topic><topic>Cholangitis, Sclerosing</topic><topic>Clinical trials</topic><topic>Deoxycholic acid</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Fibroblast Growth Factors</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metronidazole</topic><topic>News & Views</topic><topic>news-and-views</topic><topic>Phosphatases</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gerussi, Alessio</creatorcontrib><creatorcontrib>Invernizzi, Pietro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Gastroenterology & hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gerussi, Alessio</au><au>Invernizzi, Pietro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Better end points needed in primary sclerosing cholangitis trials</atitle><jtitle>Nature reviews. Gastroenterology & hepatology</jtitle><stitle>Nat Rev Gastroenterol Hepatol</stitle><addtitle>Nat Rev Gastroenterol Hepatol</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>16</volume><issue>3</issue><spage>143</spage><epage>144</epage><pages>143-144</pages><issn>1759-5045</issn><eissn>1759-5053</eissn><abstract>A new study of a fibroblast growth factor 19 analogue in patients with primary sclerosing cholangitis (PSC) provides provocative results. The data challenge alkaline phosphatase levels as the appropriate surrogate end point in PSC trials and highlight alternatives, urging efforts to identify better clinical end points for this disease.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30655632</pmid><doi>10.1038/s41575-019-0110-5</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-5086-0514</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1759-5045 |
| ispartof | Nature reviews. Gastroenterology & hepatology, 2019-03, Vol.16 (3), p.143-144 |
| issn | 1759-5045 1759-5053 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179406158 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 692/308/2779/109 692/308/409 692/699/1503/1607/2744 692/700/565/1436 Alkaline phosphatase Analysis Bile acids Biomedicine Cholangitis Cholangitis, Sclerosing Clinical trials Deoxycholic acid Double-Blind Method Drug therapy Fibroblast Growth Factors Gastroenterology Hepatology Homeostasis Humans Liver Liver diseases Medicine Medicine & Public Health Metronidazole News & Views news-and-views Phosphatases Surgery |
| title | Better end points needed in primary sclerosing cholangitis trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A05%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Better%20end%20points%20needed%20in%20primary%20sclerosing%20cholangitis%20trials&rft.jtitle=Nature%20reviews.%20Gastroenterology%20&%20hepatology&rft.au=Gerussi,%20Alessio&rft.date=2019-03-01&rft.volume=16&rft.issue=3&rft.spage=143&rft.epage=144&rft.pages=143-144&rft.issn=1759-5045&rft.eissn=1759-5053&rft_id=info:doi/10.1038/s41575-019-0110-5&rft_dat=%3Cgale_proqu%3EA576092705%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2186151251&rft_id=info:pmid/30655632&rft_galeid=A576092705&rfr_iscdi=true |